ATE348614T1 - 2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit - Google Patents

2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit

Info

Publication number: ATE348614T1
Authority: AT; Austria
Prior art keywords: npy5; neuropeptide; phenylamino; obesity; piperidine
Prior art date: 2003-07-30

Application number

AT04763608T

Other languages

English (en)

Inventor

Jover Antoni Torrens

Prio Josep Mas

Escasany Maria Angeles Fisas

Zueras Alberto Dordal

Original Assignee

Esteve Labor Dr

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2003-07-30

Filing date

2004-07-29

Publication date

2007-01-15

2004-07-29 Application filed by Esteve Labor Dr filed Critical Esteve Labor Dr

2007-01-15 Application granted granted Critical

2007-01-15 Publication of ATE348614T1 publication Critical patent/ATE348614T1/de

Links

QKEJINSRUPZPNG-UHFFFAOYSA-N 2-(4-anilinopiperidin-1-yl)-n-phenylacetamide Chemical class C=1C=CC=CC=1NC(=O)CN(CC1)CCC1NC1=CC=CC=C1 QKEJINSRUPZPNG-UHFFFAOYSA-N 0.000 title 1
208000008589 Obesity Diseases 0.000 title 1
150000001875 compounds Chemical class 0.000 title 1
239000003446 ligand Substances 0.000 title 1
235000020824 obesity Nutrition 0.000 title 1

Classifications

- C—CHEMISTRY; METALLURGY
- C04—CEMENTS; CONCRETE; ARTIFICIAL STONE; CERAMICS; REFRACTORIES
- C04B—LIME, MAGNESIA; SLAG; CEMENTS; COMPOSITIONS THEREOF, e.g. MORTARS, CONCRETE OR LIKE BUILDING MATERIALS; ARTIFICIAL STONE; CERAMICS; REFRACTORIES; TREATMENT OF NATURAL STONE
- C04B35/00—Shaped ceramic products characterised by their composition; Ceramics compositions; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/622—Forming processes; Processing powders of inorganic compounds preparatory to the manufacturing of ceramic products
- C04B35/626—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B
- C04B35/63—Preparing or treating the powders individually or as batches ; preparing or treating macroscopic reinforcing agents for ceramic products, e.g. fibres; mechanical aspects section B using additives specially adapted for forming the products, e.g.. binder binders
- C04B35/632—Organic additives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D211/56—Nitrogen atoms
- C07D211/58—Nitrogen atoms attached in position 4
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Veterinary Medicine (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Diabetes (AREA)
Ceramic Engineering (AREA)
Pain & Pain Management (AREA)
Manufacturing & Machinery (AREA)
Obesity (AREA)
Hematology (AREA)
Psychiatry (AREA)
Heart & Thoracic Surgery (AREA)
Structural Engineering (AREA)
Endocrinology (AREA)
Immunology (AREA)
Rheumatology (AREA)
Materials Engineering (AREA)
Cardiology (AREA)
Inorganic Chemistry (AREA)
Nutrition Science (AREA)
Physical Education & Sports Medicine (AREA)
Emergency Medicine (AREA)
Orthopedic Medicine & Surgery (AREA)
Hospice & Palliative Care (AREA)
Child & Adolescent Psychology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

AT04763608T 2003-07-30 2004-07-29 2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit ATE348614T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
ES200301813A ES2222833B1 (es)	2003-07-30	2003-07-30	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.

Publications (1)

Publication Number	Publication Date
ATE348614T1 true ATE348614T1 (de)	2007-01-15

Family

ID=34130546

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
AT04741322T ATE348615T1 (de)	2003-07-30	2004-07-29	2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit
AT04763608T ATE348614T1 (de)	2003-07-30	2004-07-29	2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
AT04741322T ATE348615T1 (de)	2003-07-30	2004-07-29	2-(4-(2-hydroxymethyl-phenylamino)-piperidin-1- yl)-n-(9h-carbazol-3-yl) - acetamid derivate und verwandte verbindungen als neuropeptide y5 (npy5) liganden zur behandlung von fettleibigkeit

Country Status (19)

Country	Link
US (4)	US7888510B2 (de)
EP (2)	EP1648458B1 (de)
JP (2)	JP2007500162A (de)
CN (2)	CN1829516A (de)
AR (1)	AR045154A1 (de)
AT (2)	ATE348615T1 (de)
AU (2)	AU2004262482A1 (de)
BR (2)	BRPI0412860A (de)
CA (2)	CA2534096A1 (de)
DE (2)	DE602004003829T2 (de)
ES (3)	ES2222833B1 (de)
MX (2)	MXPA06001226A (de)
MY (1)	MY136965A (de)
NO (2)	NO20060553L (de)
PE (1)	PE20050332A1 (de)
PT (2)	PT1651220E (de)
RU (2)	RU2006105792A (de)
TW (1)	TW200510379A (de)
WO (2)	WO2005013988A1 (de)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US9560804B1 (en)	2010-12-15	2017-02-07	Marion Calmer	Stalk roll with flutes defining a recess
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.
EP1918281A1 (de) *	2006-11-02	2008-05-07	Laboratorios del Dr. Esteve S.A.	Phenylamino-substituierte piperidine Verbindungen, ihre Herstellung und Verwendung als Arzneimittel
JP2010519206A (ja) *	2007-02-16	2010-06-03	シンタファーマシューティカルズコーポレーション	炎症及び免疫関連使用のための置換縮合環化合物
WO2010053861A2 (en) *	2008-11-07	2010-05-14	H. Lundbeck A/S	Biologically active amides
AU2021324684A1 (en) *	2020-08-11	2023-04-20	Board Of Trustees Of Michigan State University	Proteasome enhancers and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1328197A (en)	1995-12-01	1997-06-19	Synaptic Pharmaceutical Corporation	Aryl sulfonamide and sulfamide derivatives and uses thereof
AU7692996A (en)	1995-12-01	1997-06-27	Ciba-Geigy Ag	Receptor antagonists
CA2273102A1 (en)	1996-12-03	1998-06-11	Banyu Pharmaceutical Co., Ltd.	Urea derivatives
WO1998035957A1 (en) *	1997-02-14	1998-08-20	Bayer Corporation	Amide derivatives as selective neuropeptide y receptor antagonists
US6048900A (en) *	1998-02-13	2000-04-11	Bayer Corporation	Amide derivatives and methods for using the same as selective neuropeptide Y receptor antagonists
AU6309698A (en)	1997-03-12	1998-09-29	Banyu Pharmaceutical Co., Ltd.	Drugs containing aminopyridine derivatives as the active ingredient
US7534857B2 (en) *	1997-12-19	2009-05-19	Centegen, Inc.	Methods and compositions for the treatment and prevention of staphylococcal infections
US6187777B1 (en)	1998-02-06	2001-02-13	Amgen Inc.	Compounds and methods which modulate feeding behavior and related diseases
US6201025B1 (en)	1998-10-07	2001-03-13	Ortho-Mcneil Pharmaceutical, Inc.	N-aralkylaminotetralins as ligands for the neuropeptide Y Y5 receptor
WO2001007409A1 (en) *	1999-07-23	2001-02-01	Astrazeneca Uk Limited	Carbazole derivatives and their use as neuropeptide y5 receptor ligands
US6399631B1 (en) *	1999-07-23	2002-06-04	Pfizer Inc.	Carbazole neuropeptide Y5 antagonists
WO2001009120A1 (en) *	1999-07-28	2001-02-08	Ortho-Mcneil Pharmaceutical, Inc.	Amine and amide derivatives as ligands for the neuropeptide y y5 receptor useful in the treatment of obesity and other disorders
CA2381111A1 (en)	1999-08-26	2001-03-01	Leah M. Giupponi	Npy antagonists: spiroisoquinolinone derivatives
CA2453383C (en) *	2001-07-24	2010-04-06	Richter Gedeon Vegyeszeti Gyar Rt	Piperidine derivatives as nmda receptor antagonists
US7067549B2 (en) *	2001-12-31	2006-06-27	Actelion Pharmaceuticals Ag	Pyrrolidone carboxamides
ES2193875B2 (es) *	2002-04-09	2005-03-01	Laboratorios Del Dr. Esteve, S.A.	Derivados de benzoxazinona, su preparacion y su aplicacion como medicamentos.
ES2228267B1 (es) *	2003-07-30	2006-07-01	Laboratorios Del Dr. Esteve, S.A.	Combinacion de sustancias activas conteniendo al menos un compuesto con afinidad por el receptor del neuropeptido y (npy) y al menos un compuesto con afinidad por el receptor 5-ht6.
ES2222833B1 (es) *	2003-07-30	2006-03-01	Laboratorios Del Dr. Esteve, S.A.	Compuestos piperidinicos 1,4-disustituidos, su preparacion y su uso como medicamentos.

2003
- 2003-07-30 ES ES200301813A patent/ES2222833B1/es not_active Expired - Fee Related
2004
- 2004-07-29 BR BRPI0412860-5A patent/BRPI0412860A/pt not_active IP Right Cessation
- 2004-07-29 AU AU2004262482A patent/AU2004262482A1/en not_active Abandoned
- 2004-07-29 MX MXPA06001226A patent/MXPA06001226A/es not_active Application Discontinuation
- 2004-07-29 MY MYPI20043075A patent/MY136965A/en unknown
- 2004-07-29 RU RU2006105792/04A patent/RU2006105792A/ru unknown
- 2004-07-29 PT PT04741322T patent/PT1651220E/pt unknown
- 2004-07-29 DE DE602004003829T patent/DE602004003829T2/de not_active Expired - Lifetime
- 2004-07-29 JP JP2006521526A patent/JP2007500162A/ja active Pending
- 2004-07-29 EP EP04763608A patent/EP1648458B1/de not_active Expired - Lifetime
- 2004-07-29 PT PT04763608T patent/PT1648458E/pt unknown
- 2004-07-29 BR BRPI0413091-0A patent/BRPI0413091A/pt not_active Application Discontinuation
- 2004-07-29 EP EP04741322A patent/EP1651220B1/de not_active Expired - Lifetime
- 2004-07-29 JP JP2006521533A patent/JP2007500169A/ja active Pending
- 2004-07-29 DE DE602004003831T patent/DE602004003831T2/de not_active Expired - Lifetime
- 2004-07-29 MX MXPA06001140A patent/MXPA06001140A/es not_active Application Discontinuation
- 2004-07-29 WO PCT/EP2004/008508 patent/WO2005013988A1/en not_active Ceased
- 2004-07-29 TW TW093122665A patent/TW200510379A/zh unknown
- 2004-07-29 CA CA002534096A patent/CA2534096A1/en not_active Abandoned
- 2004-07-29 AT AT04741322T patent/ATE348615T1/de not_active IP Right Cessation
- 2004-07-29 AT AT04763608T patent/ATE348614T1/de not_active IP Right Cessation
- 2004-07-29 AU AU2004262491A patent/AU2004262491A1/en not_active Abandoned
- 2004-07-29 US US10/565,979 patent/US7888510B2/en not_active Expired - Fee Related
- 2004-07-29 AR ARP040102696A patent/AR045154A1/es unknown
- 2004-07-29 CN CNA2004800219418A patent/CN1829516A/zh active Pending
- 2004-07-29 ES ES04741322T patent/ES2279400T3/es not_active Expired - Lifetime
- 2004-07-29 US US10/566,399 patent/US20070105853A1/en not_active Abandoned
- 2004-07-29 WO PCT/EP2004/008517 patent/WO2005013990A1/en not_active Ceased
- 2004-07-29 CN CNA2004800222637A patent/CN1832745A/zh active Pending
- 2004-07-29 RU RU2006105711/04A patent/RU2006105711A/ru unknown
- 2004-07-29 CA CA002534101A patent/CA2534101A1/en not_active Abandoned
- 2004-07-29 ES ES04763608T patent/ES2279419T3/es not_active Expired - Lifetime
- 2004-08-02 PE PE2004000734A patent/PE20050332A1/es not_active Application Discontinuation
2006
- 2006-02-02 NO NO20060553A patent/NO20060553L/no not_active Application Discontinuation
- 2006-02-07 NO NO20060605A patent/NO20060605L/no not_active Application Discontinuation
2010
- 2010-07-12 US US12/834,211 patent/US20100280072A1/en not_active Abandoned
2011
- 2011-01-06 US US12/985,646 patent/US20110172270A1/en not_active Abandoned

Also Published As

Publication number	Publication date
NO20060605L (no)	2006-02-07
MXPA06001226A (es)	2006-05-15
US20110172270A1 (en)	2011-07-14
BRPI0413091A (pt)	2006-10-03
MXPA06001140A (es)	2006-04-24
US20070105853A1 (en)	2007-05-10
US20100280072A1 (en)	2010-11-04
US20080119516A1 (en)	2008-05-22
DE602004003831T2 (de)	2007-10-25
EP1648458B1 (de)	2006-12-20
CN1832745A (zh)	2006-09-13
AR045154A1 (es)	2005-10-19
DE602004003829T2 (de)	2007-09-20
NO20060553L (no)	2006-02-02
ATE348615T1 (de)	2007-01-15
ES2279419T3 (es)	2007-08-16
CA2534101A1 (en)	2005-02-17
RU2006105792A (ru)	2007-09-20
EP1651220A1 (de)	2006-05-03
DE602004003829D1 (de)	2007-02-01
PT1651220E (pt)	2007-03-30
CA2534096A1 (en)	2005-02-17
DE602004003831D1 (de)	2007-02-01
WO2005013990A1 (en)	2005-02-17
PE20050332A1 (es)	2005-06-12
EP1648458A1 (de)	2006-04-26
EP1651220B1 (de)	2006-12-20
JP2007500162A (ja)	2007-01-11
ES2222833A1 (es)	2005-02-01
PT1648458E (pt)	2007-03-30
AU2004262482A1 (en)	2005-02-17
BRPI0412860A (pt)	2006-10-03
WO2005013988A1 (en)	2005-02-17
RU2006105711A (ru)	2007-09-20
JP2007500169A (ja)	2007-01-11
CN1829516A (zh)	2006-09-06
ES2222833B1 (es)	2006-03-01
MY136965A (en)	2008-12-31
AU2004262491A1 (en)	2005-02-17
TW200510379A (en)	2005-03-16
ES2279400T3 (es)	2007-08-16
US7888510B2 (en)	2011-02-15
WO2005013988A8 (en)	2006-11-09

Legal Events

Date

Code

Title

Description

2007-08-15

UEP

Publication of translation of european patent specification

Ref document number: 1648458

Country of ref document: EP

2010-04-15

REN

Ceased due to non-payment of the annual fee

Publication	Publication Date	Title
ATE365039T1 (de)	2007-07-15	4-(4-(heterocyclylalkoxy phenyl)-1-(heterocyclyl- carbonyl)piperidin derivate und verwandte verbindungen als histamin h3 antagonsiten zur behandlung von neurologischen erkrankungen wie alzheimer's
ATE551059T1 (de)	2012-04-15	Fasudil in kombination mit bosentan zur behandlung von pulmonaler arterieller hypertonie
NO20161012A1 (no)	2016-06-15	Farmasøytisk sammensetning omfattende polymorfe former av 3-(4-amino-1-okso-1,3-dihydro-isoindol-2-yl)-piperidin-1,6-dion
DE602004009323D1 (de)	2007-11-15	1-(2-amino-benzoyl)-piperazin-derivate als glycin-aufnahmehemmer zur behandlung von psychosen
DE602004022187D1 (de)	2009-09-03	4-(pyrazol-3-ylamino)pyrimidinderivate zur verwendung bei der behandlung von krebs
DE60212146D1 (de)	2006-07-20	Piperidin derivate als ccr5 rezeptor antagonisten zur behandlung von hiv
DE602007010303D1 (de)	2010-12-16	Verwendung von 3- (4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidin--2,6-dion zur behandlung von mantelzelllymphomen
ATE361296T1 (de)	2007-05-15	Pyrazolidin-1,2-dicarbonsäure-1-((phenyl)-amid) 2-((phenyl)-amid) derivate als koagulationsfaktor xa inhibitoren zur behandlung von thrombosen
ATE297917T1 (de)	2005-07-15	4-(aminomethyl)-piperidinbenzamide zur behandlung von gastrointestinalen störungen
DE602004003952D1 (de)	2007-02-08	Substituierte tetrahydrobenzothienopyrimidinamine verbindungen geeignet zur behandlung von hyper-proliferative disorders
DE50313157D1 (de)	2010-11-18	Phenylaminopyrimidine und ihre verwendung als rho-kinase inhibitoren
ATE347550T1 (de)	2006-12-15	Polymorph von 4-(2-(4-(1-(2-ethoxyethyl)-1h- benzimidazol-2-yl)-1-piperidinyl)ethyl)-alpha, alpha-dimethylbenzolessigsäure
ATE435217T1 (de)	2009-07-15	4-(3- (2-phenyl-oxazol-4-ylmethoxy)- cyclohexyloxy)-butansäure derivate und verwandte verbindungen als ppar modulatoren zur behandlung von typ 2 diabetes und atherosklerose
ATE348614T1 (de)	2007-01-15	2-(4-(phenylamino)-piperidin-1-yl)-n-phenyl- acetamid derivate und verwandte verbindungen als neuropeptid y5 (npy5) liganden zur behandlung von fettleibigkeit
DE60332862D1 (de)	2010-07-15	17beta-hydroxysteroid dehydrogenase typ-3 hemmer zur behandlung von androgen abhängigen erkrankungen
MA28547B1 (fr)	2007-04-03	Chlorhydrate de [4-(5-aminomethyl-2-fluoro-phenyl)- piperidin-1-yl]-(4-bromo-3-methyl-5-propoxy-thiophen-2-yl)-methanone en tant qu'inhibiteur de tryptase de mastocyte
ATE434438T1 (de)	2009-07-15	Kombination enthaltend einen inhibitor der signaltransduktion und ein epothilonderivat
DE602005017373D1 (de)	2009-12-10	Verbindungen zur behandlung von schizophrenie und/oder glucoregulatorische auffälligkeiten
ATE504580T1 (de)	2011-04-15	Malonsäureamidderivate als inhibitoren von g- sekretase zur behandlung von alzheimer-krankheit
ATE337779T1 (de)	2006-09-15	N-'4-(2-imino-pyrrolidin-1-yl)phenyl)-acetemid- und entsprechende piperidinderivate als faktor xa inhibitoren zur behandlung von thromboembolischen erkrankungen
ATE277053T1 (de)	2004-10-15	2-(4-pyridinyl)-benzofurane zur verwendung als metalloprotease-inhibitoren
ATE348611T1 (de)	2007-01-15	Derivate des phenoxy-n-'4-(isothiazolidin-1,1- dioxid-2yl)pheny)-valerian-säureamids und andere verbindungen als inhibitoren des koagulationsfaktors xa zur behandlung von thromboembolischen erkrankungen und tumoren
DE602004001492D1 (de)	2006-08-24	(3-(4-(Pyridin-2-ylamino)-butyryl)-2,3,4,4a,9,9a-hexahydro-1H-3-aza-fluoren-9-yl)-essigsäure Derivate und verwandte tricyclische Indanyle als alphaVbeta3 und alphaVbeta5 Integrin Inhibitoren zur Behandlung von Krebs und instabiler Angina
ATE390413T1 (de)	2008-04-15	4-(2-phenylsulfanyl-phenyl)-1,2,3,6- tetrahydropyridinderivaten zur verwendung als serotonin-wiederaufnahmehemmer
NO20052803L (no)	2005-09-16	Komplekser av e-2-metoksy-n-(3-{4-(3-metyl-pyridin-3-yloksy)-fenylam ino)-kinazolin-6-yl}-allyl)acetamid, deres fremstillingsmate og bruk